Default company panoramic image
Logo

VetDC

VetDC is a cancer-focused veterinary biotechnology company that adapts innovative, human biotechnologies for use in companion animals.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Fort Collins, CO, USA
  • Currency USD
  • Founded August 2009
  • Employees 5
  • Website vet-dc.com

Company Summary

By focusing on programs that have already completed preclinical testing, VetDC selects technologies with the most desirable product profiles - resulting in less risk, fast time to market and capital preservation. Our lead candidate, VDC-1101, is a novel anti-cancer agent licensed from Gilead Sciences with extensive data in pet dogs with lymphoma. VDC-1101 has a favorable safety, efficacy and dosing profile and is poised for a 2014 launch.

Team

  • Default avatar
    Steven J. Roy
    President & CEO

    Mr. Roy has extensive biotechnology commercialization and business development expertise, with over 13 years at Amgen Inc. He headed up Strategy, Planning and Operations for the launch of Aranesp®, a multi-billion dollar oncology drug. As Director of Amgen's Department of Alliance Management, he managed ~70 corporate partnerships, representing over $100 Million in annual R&D expenditure.

  • Default avatar
    Ann Donoghue
    Sr. Dir. Pdct. Dev. & Reg. Affairs

    Dr. Donoghue has 20 years in the drug development field, at Hoechst-Roussel Agri-Vet Company, Heska Corporation and PR Pharmaceuticals, Inc. with 4 NADAs, 3 USDA licenses and 2 EPA registrations. She has extensive regulatory experience across both animal and human programs, from project initiation through scale up to commercial GMP manufacturing, and GLP/GCP clinical trials.

  • Default avatar
    Doug Johnson
    Head of Manufacturing

    Dr. Johnson has 20 years of experience in the pharmaceutical industry covering all areas of CMC activities. Doug Johnson spent over 10 years as Vice President of Manufacturing and Pharmaceutical Sciences at Allos Therapeutics, managing and integrating outsourced chemistry and manufacturing activities for small molecule cancer drugs. He has been involved in the preparation of 4 NDAs and 10 INDs.

  • Default avatar
    Doug Thamm
    Head of Clinical Affairs

    Dr. Thamm is an ACVIM Diplomat and Associate Professor of Oncology at Colorado State University. He has extensive oncology clinical experience, conducting over 24 animal cancer trials and was one of the lead veterinary investigators on VDC-1101. Dr. Thamm is an internationally recognized veterinary cancer opinion leader.

  • Default avatar
    Terry Opgenorth
    Chief Scientific Officer

    Dr. Opgenorth has over 20 years of biopharmaceutical R&D experience. As a former Divisional Vice President of Discovery Research at Abbott Laboratories, he led teams that brought 10 compounds from discovery research into human clinical trials. Dr. Opgenorth is a VetDC founder and is Vice President, CSU Ventures.

Advisors

  • Default avatar
    Bill Roberts, Roberts & Olivia
    Lawyer
    Unconfirmed
    Default avatar
    Kurtz Fargo, LLP
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Colorado Institute for Drug, Device and Diagnostic Development (CID4)
    Unconfirmed
    Default avatar
    CSU Ventures
    Unconfirmed
    Default avatar
    Angel Investors (Rockies Venture Club, High Altitude Investors, etc)
    Unconfirmed